logo
Share SHARE
FONT-SIZE Plus   Neg

Aerie Pharmaceuticals Inc. (AERI) Leaped To A New High After FDA Review

The FDA posted a preliminary review on its website Wednesday which states that Aerie Pharmaceuticals Inc.'s (AERI) Rhopressa, a treatment for glaucoma, is effective in lowering eye pressure.

Aerie Pharmaceuticals gapped open sharply higher Wednesday, but traded in a range for the majority of the session. Shares finished with a gain of 8.95 at $64.30 on above average volume. The stock surged past resistance and set a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT